Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: Expert Rev Anticancer Ther. 2009 Feb;9(2):235–245. doi: 10.1586/14737140.9.2.235

Figure 3. Rationale for combining RTK-targeted and mTOR-targeted therapies.

Figure 3

Arrow thickness is proportional to signal strength. Font weight of ‘malignancy’ is proportional to malignant effects.

LIG: Ligand; PIP2: Phosphatidylinositol-3,4,-bisphosphate; PIP3: Phosphatidylinositol-3,4,5-triphosphate; RTK: Receptor tyrosine kinase.